Seattle Genetics’ Medical Point Man, Tom Reynolds, Aims to Capitalize on Hodgkin’s Drug

Biotech, cancer, Seattle Genetics Luke Timmerman wrote: The people at Seattle Genetics think they have a blockbuster-drug-in-the-making for Hodgkin’s disease. Tom Reynolds is the guy whose job it is to prove it to the world. Few drugs ever demonstrate the kind of promise SGN-35 did in its initial clinical trial in June, says Reynolds, the company’s chief medical officer. The drug showed about half of patients had partial or total elimination of their tumors, even at much lower-than-expected doses, with limited side effects for a cancer drug. “This sounds like Gleevec.